Sydney Kamlager-Dove addresses court rulings on reproductive care and Black representation

Congresswoman Sydney Kamlager-Dove, who represents California’s 37th district in the U.S. Congress, recently posted a series of statements on her Twitter account addressing reproductive care access and voting rights.

On May 2, 2026, Kamlager-Dove responded to a court decision affecting reproductive healthcare by stating, “This is a devastating blow to access to reproductive care. This ruling puts the policies of anti-abortion extremists over the FDA’s science-based regulations.

We will appeal this rogue ruling. Mifepristone is safe and must remain accessible, as it has been for over 25 years.”

Two days later, on May 4, she commented on a development regarding tele-health and mail access to mifepristone: “I am relieved that tele-health and mail access to Mifepristone has been temporarily restored.

But this is just the beginning. We must keep fighting to ensure Mifepristone remains a safe and an essential form of reproductive care, as it has been for 25 years.”

That same day, Kamlager-Dove addressed issues related to representation and voting rights: “Most Black Members of Congress, like me, are not from majority-Black districts. @TheBlackCaucus works for ALL Americans to ensure a rising tide lifts all boats.

While we fight back against SCOTUS’ ruling that dilutes Black voting power, we’ll keep representing the people.”

Sydney Kamlager-Dove began serving in Congress in 2023 after replacing Karen Bass. She previously served in both the California State Assembly (2018–2021) and California Senate (2021–2023). Born in Chicago in 1972 and currently residing in Los Angeles, Kamlager-Dove holds a BA from the University of Southern California (FACTS 1-4).